Back to top
more

Ligand Pharmaceuticals (LGND)

(Real Time Quote from BATS)

$79.97 USD

79.97
18,123

+0.58 (0.73%)

Updated Jun 24, 2024 01:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Ginkgo (DNA) to Report Q3 Earnings: What's in the Cards?

On Ginkgo's (DNA) third-quarter earnings call, investor focus is likely to be on the sales performance of its two business units ¿¿¿ Biosecurity and Cell Engineering.

Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?

Catalyst's (CPRX) third-quarter 2023 earnings are expected to have been driven by the robust performances of its two marketed drugs, Firdapse and Fycompa CIII.

Bausch Health (BHC) Q3 Earnings & Sales Beat, '23 View Updated

Bausch (BHC) surpasses third-quarter earnings and sales estimates as most of the business units post growth.

Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised

Intra-Cellular (ITCI) third-quarter 2023 earnings and revenues beat estimates. Caplyta sales continue to drive growth. The company raises its guidance for full-year 2023 Caplyta sales.

ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues

ImmunoGen's (IMGN) third-quarter 2023 earnings and revenues surpass estimates, driven by strong adoption of its sole-marketed drug Elahere. The company reiterates its revenue guidance.

Puma Biotech (PBYI) Q3 Earnings Beat, Revenues Lag Estimates

Puma Biotech's (PBYI) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens the full-year revenue guidance.

Moderna (MRNA) Beats on Q3 Earnings & Sales, Expects Lower COVID Demand

Moderna (MRNA) beats expectations for earnings and sales. However, the company projects lower-than-expected 2024 guidance, which likely led to a decline in share price after the earnings announcement.

Sarepta (SRPT) Q3 Loss Narrower Than Expected, Sales Beat

Sarepta's (SRPT) Q3 earnings and sales beat estimates on the back of strong sales for recently approved DMD gene therapy Elevidys.

BioMarin (BMRN) Q3 Earnings in Line, Sales Miss, '23 View Cut

BioMarin's (BMRN) Q3 earnings are in line with estimates but miss the mark on sales. The company lowered its 2023 guidance due to global pricing and reimbursement delays for Roctavian.

Zoetis' (ZTS) Q3 Earnings Beat, Revenues Miss by a Whisker

Zoetis' (ZTS) third-quarter 2023 earnings surpass estimates. However, revenues fall marginally short. The strong performance of the companion animal portfolio drives year-over-year revenues.

Exelixis (EXEL) Q3 Earnings and Sales Miss, Annual View Updated

Exelixis (EXEL) misses third-quarter 2023 earnings and sales estimates but tightens its annual revenue guidance and increases its R&D guidance.

Apellis (APLS) Q3 Loss Wider Than Expected, Syfovre Drives Sales

Apellis' (APLS) third-quarter 2023 bottom line misses estimates, while the top line beats the same. Newly approved product, Syfovre, drives sales in the reported quarter.

Ligand Pharmaceuticals (LGND) Laps the Stock Market: Here's Why

In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $53.30, indicating a +1.93% shift from the previous trading day.

GSK Beats on Q3 Earnings and Sales, Raises 2023 Guidance

GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales on the back of strong RSV vaccine sales.

Ligand Pharmaceuticals (LGND) Earnings Expected to Grow: Should You Buy?

Ligand (LGND) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Charles River (CRL) to Report Q3 Earnings: What's in Store?

Charles River's (CRL) CRADLE initiative and research models in North America and China are anticipated to have maintained their growth momentum in the third quarter.

Novo Nordisk (NVO) to Report Q3 Earnings: What's in the Cards?

Novo Nordisk (NVO) is likely to outperform third-quarter 2023 estimates, driven by increased Diabetes and Obesity Care product sales despite severe rivalry and pricing pressure in the United States.

Amgen (AMGN) Beats on Q3 Earnings Beat, Lags Sales, Ups View

Amgen (AMGN) beats Q3 estimates for earnings but misses on sales. Following the acquisition of Horizon Therapeutics, it raises earnings and sales guidance for 2023.

Perrigo (PRGO) to Report Q3 Earnings: What's in the Cards?

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.

Viatris (VTRS) to Report Q3 Earnings: Is a Beat in Store?

Viatris' (VTRS) Q3 results are likely to have been boosted by the momentum in its branded and generic businesses.

Gilead (GILD) Gears Up to Report Q3 Earnings: What's in Store?

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its third-quarter 2023 results.

Swedish Orphan Biovitrum (BIOVF) Q3 Earnings Miss Estimates

Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of -44.44% and 7.69%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Regeneron (REGN) to Report Q3 Earnings: What's in the Cards?

Investors' focus is likely to be on the performance of lead drug Eylea and the uptake of Eylea HD when Regeneron (REGN) reports its third-quarter 2023 results.

Ligand Pharmaceuticals (LGND) Advances While Market Declines: Some Information for Investors

In the latest trading session, Ligand Pharmaceuticals (LGND) closed at $51.06, marking a +1.53% move from the previous day.

LGND vs. ILMN: Which Stock Is the Better Value Option?

LGND vs. ILMN: Which Stock Is the Better Value Option?